ASH 2018 dr. Peter Westerweel

ASH 2018 dr. Peter Westerweel, werkzaam in het Albert Schweitzer Ziekenhuis te Dordrecht


International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a Gimema and HOVON Study


Ask Speakers


Medical Information Request